HR 2387

STOP GAMES Act of 2019

Congress: 116 (2019–2021, Ended)
Chamber: House
Policy Area: Health
Introduced: Apr 29, 2019
Current Status: Forwarded by Subcommittee to Full Committee by Voice Vote .
Latest Action: Forwarded by Subcommittee to Full Committee by Voice Vote . (Nov 13, 2019)
Official Text: https://www.congress.gov/bill/116th-congress/house-bill/2387

Sponsor

Name: Rep. Levin, Andy [D-MI-9]
Party: Democratic • **State:** MI • **Chamber:** House

Cosponsors (11 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Rooney, Francis [R-FL-19]	R · FL		Apr 29, 2019
Rep. Doggett, Lloyd [D-TX-35]	D · TX		May 30, 2019
Rep. Garamendi, John [D-CA-3]	D · CA		Jun 3, 2019
Rep. Tonko, Paul [D-NY-20]	D · NY		Jun 3, 2019
Rep. Khanna, Ro [D-CA-17]	D · CA		Jun 13, 2019
Rep. Johnson, Eddie Bernice [D-TX-30]	D · TX		Jun 19, 2019
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Jul 16, 2019
Rep. Green, Al [D-TX-9]	D · TX		Jul 18, 2019
Rep. Axne, Cynthia [D-IA-3]	D · IA		Jul 25, 2019
Rep. Tlaib, Rashida [D-MI-13]	D · MI		Aug 27, 2019
Rep. Welch, Peter [D-VT-At Large]	D · VT		Sep 18, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Reported by	Nov 13, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Apr 29, 2019)

Stop The Overuse of Petitions and Get Affordable Medicines to Enter Soon Act of 2019 or the STOP GAMES Act of 2019

This bill specifies factors that the Food and Drug Administration (FDA) must use in determining if a petition is submitted with the primary purpose of delaying the approval of a pending new or generic drug application. (Current law allows third parties, including interested parties, to file petitions asking the FDA to take various actions, such as to consider certain issues pertaining to an application for market approval for a drug; current law also allows the FDA to deny a petition that is submitted with the primary purpose of delaying approval of an application.)
The factors include (1) whether the petitioner filed serial petitions raising issues that could have been known to the petitioner when an earlier petition was filed, and (2) whether the petition has any data or information to support its scientific positions.

If the FDA finds that delay is the primary purpose of the petition, it must refer the matter to the Federal Trade Commission.

A party filing a petition must do so within 60 days of when the party first learned of the information on which the petition is based.

Actions Timeline

- **Nov 13, 2019:** Subcommittee Consideration and Mark-up Session Held.
- **Nov 13, 2019:** Forwarded by Subcommittee to Full Committee by Voice Vote .
- **Apr 30, 2019:** Referred to the Subcommittee on Health.
- **Apr 29, 2019:** Introduced in House
- **Apr 29, 2019:** Referred to the House Committee on Energy and Commerce.